The ubiquitin-proteasome pathway in cancer
1998

The Ubiquitin-Proteasome Pathway in Cancer

publication Evidence: high

Author Information

Author(s): V Spataro, C Norbury, AL Harris

Primary Institution: Imperial Cancer Research Fund, Molecular Oncology Laboratory, University of Oxford

Hypothesis

The ubiquitin-proteasome pathway is often targeted for deregulation in cancer, affecting processes like oncogenic transformation and drug resistance.

Conclusion

The ubiquitin-proteasome pathway plays a crucial role in cancer biology, influencing tumor progression and response to treatment.

Supporting Evidence

  • The ubiquitin-proteasome pathway regulates key proteins involved in the cell cycle and immune response.
  • Alterations in this pathway can lead to oncogenic transformation and drug resistance.
  • Low levels of the protein p27 are associated with poor prognosis in colorectal and breast cancers.
  • Proteasome activity is linked to the degradation of important cell cycle regulators.

Takeaway

This study talks about how a system in our cells that breaks down proteins can go wrong in cancer, making it harder to treat.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication